GlassScriptPhysician profile
Ronak Dilip Patel
NPI 1114273893
$6,420.81
in general payments reported to CMS, 2019-2025
21 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $657 · 2021: $1,003 · 2022: $1,030 · 2023: $1,335 · 2024: $731 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,185.71 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbott Laboratories | $539.05 | 2019-2025 | Proclaim, Eterna, Octrode |
| Collegium Pharmaceutical, INC. | $411.57 | 2019-2025 | Belbuca, Xtampza |
| Si-Bone, INC. | $290.04 | 2020-2024 | |
| Nevro Corp. | $206.10 | 2019-2022 | |
| Nuvasive, INC. | $127.09 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $124.09 | 2025 | Exparel |
| Stryker Corporation | $118.91 | 2023 | Vitoss, Actishield |
| Depuy Synthes Sales INC. | $97.23 | 2019-2025 | Orthovisc, Monovisc |
| Insulet Corporation | $63.75 | 2019-2022 | |
| Vertos Medical, INC. | $40.71 | 2024 | Mild Device Kit |
| Hikma Pharmaceuticals USA | $37.59 | 2022 | |
| Globus Medical, INC. | $31.90 | 2025 | Senza |
| Fidia Pharma USA INC. | $31.87 | 2020-2021 | |
| Horizon Therapeutics Plc | $28.20 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $17.00 | 2025 | |
| Lilly USA, LLC | $15.32 | 2024 | Jardiance, Zepbound |
| Clarus Therapeutics INC. | $15.00 | 2021 | |
| Ibsa Pharma INC. | $14.54 | 2024 | Licart, Tirosint |
| Bioventus LLC | $12.70 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.